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Abstract
Background: Hepatitis C virus (HCV) infection is one of the major public health challenges generating a relevant
burden. High-risk groups, including people who inject drugs (PWID), are at serious risk for developing HCV. In recent
years, several investigations have been conducted in Iran to assess the prevalence e of HCV among PWID. The aim of
the present study was to synthesize the literature performing a comprehensive search and meta-analysis.
Methods: A comprehensive literature search was carried out from January 2000 to September 2019. Several
international databases, namely Scopus, PubMed/MEDLINE, Embase, ISI/Web of Science, PsycINFO, CINAHL, the
Cochrane Library and the Directory of Open Access Journals (DOAJ), as well as Iranian databases (Barakathns, SID and
MagIran), were consulted. Eligible studies were identified according to the following PECOS (population, exposure,
comparison/comparator, outcome and study type) criteria: i) population: Iranian population; ii) exposure: injection drug
users; iii) comparison/comparator: type of substance injected and level of substance use, iv) outcome: HCV prevalence;
and v) study type: cross-sectional study. After finding potentially related studies, authors extracted relevant data and
information based on an ad hoc Excel spreadsheet. Extracted data included the surname of the first author, the study
journal, the year of publication, the number of participants examined, the type of diagnostic test performed, the
number of positive HCV patients, the number of participants stratified by gender, the reported prevalence, the duration
of drug injection practice and the history of using a shared syringe.
Results: Forty-two studies were included. 15,072 PWID were assessed for determining the prevalence of HCV. The overall
prevalence of HCV among PWID in Iran was computed to be 47% (CI 95: 39–56). The prevalence ranged between 7 and
96%. Men and subjects using a common/shared syringe were 1.46 and 3.95 times more likely to be at risk, respectively.
Conclusion: The findings of the present study showed that the prevalence of HCV among PWIDs in Iran is high. The
support and implementation of ad hoc health-related policies and programs that reduce this should be put into action.
Keywords: Hepatitis C virus, Meta-analysis, Harm reduction policies, Health management, Iran
Background
Health policy- and decision-makers consider hepatitis C
virus (HCV) infection as one of the major health chal-
lenges in the field of public health, in that it generates a
relevant burden, both in epidemiological and clinical
terms [1]. High-risk groups such as prisoners, people with
HIV, those who receive blood products and people who
inject drugs (PWID) are at serious risk for HCV [2]. The
World Health Organization (WHO) estimates that in
2015 around 1.75 million new cases of infections occurred
worldwide. According to the WHO, the highest preva-
lence of infection was reported in the Eastern Mediterra-
nean (2.3%), and in the European (1.5%) regions [3].
Among the high-risk groups for HCV, PWID repre-
sent a category that needs to be monitored and
checked carefully [4]. Unsafe injection is one of the
main ways of transmitting HCV infection [5], in par-
ticular, the usage of common syringes, which is quite
a widespread practice among PWID [6]. The risk of
HCV infection among these people is higher than the
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risk among HIV patients. Identifying high-risk groups
can greatly help the healthcare system prevent and
control various communicable diseases [7, 8].
Chronic HCV infection can cause cirrhosis, hepatocellular
carcinoma and ultimately lead to death [9]. Due to the severe
clinical outcomes, the high costs of the treatment and the ab-
sence of effective vaccines for HCV, health policy- and
decision-makers tend to especially focus on prevention, con-
trol and management of HCV patients [10]. The WHO has
identified the HCV elimination plan for 2030 as an import-
ant, ambitious goal, and as such, one of the most important
ways to achieve this goal is to screen and control the disease
in high-risk groups such as PWID [11].
The Middle East region is one of the areas worldwide in
which HCV is highly prevalent. The risk of the transmission
and spreading of HCV among PWID has increased in the last
years as a result of the transit of drugs and addicted people
through Afghanistan and neighboring countries [12]. Iran is
one of the countries in the Eastern Mediterranean region, with
about 186,000 HCV patients [13]. According to a recently
published systematic review and meta-analysis, the prevalence
of HCV in Iran is about 0.6% [14]. Despite the fact that this
rate is lower compared to many neighboring countries in the
area, the rate among high-risk groups such as PWID has con-
siderably increased and this is a serious warning for Iranian
health policy- and decision-makers [15]. Neighborhood with
countries like Afghanistan is one of the major causes of this
increase, and the Iranian government has been trying to
mobilize all its resources to cope with this challenge [13].
In recent years, several investigations have been con-
ducted in Iran to assess the prevalence of HCV among
PWID, in order to provide planners with good evidence
that can be used to implement appropriate health-
related policies [16]. Like other countries in the world,
also in Iran people who use personal or common syrin-
ges for intravenous injections are defined as PWID [17].
Understanding the epidemiologic status can provide a
clearer and more appropriate framework for decision-and
policy-makers in the health sector. They can use this infor-
mation to develop their programs and plans in the different
areas of HCV control and management. Health policy-and
decision-makers, using available evidence, can effectively
curb the costs generated by HCV in their country.
The aim of the present study was to investigate the
prevalence of HCV among PWID by performing a com-
prehensive literature search and meta-analysis of pub-
lished studies and to critically evaluate and appraise the
policies that the health sector has been trying to imple-
ment in order to reduce the burden of HCV in Iran.
Methods
Systematic review and meta-analysis study protocol
The study protocol has been prospectively registered
within the PROSPERO database (identification ID:
CRD42019122601) [18] and the main findings are here
reported in accordance with the “Preferred Reporting
Items for Systematic Reviews and Meta-Analyses”
(PRISMA) guidelines [19].
Search strategy
A comprehensive literature search has been carried out in
order to retrieve relevant studies related to the topic under
study, from January 2000 to September 2019. Several
international databases, repositories and bibliographic the-
sauri, namely Scopus, PubMed/MEDLINE, Embase, ISI/
Web of Science, PsycINFO, CINAHL, the Cochrane Li-
brary and the Directory of Open Access Journals (DOAJ),
as well as Iranian databases (Barakathns, SID and
MagIran), have been mined independently by two re-
searchers. To minimize the chance of not capturing all
relevant studies and to find more potentially related stud-
ies, also the gray literature was consulted via Google
Scholar. Furthermore, references lists of each potentially
eligible study were evaluated and hand-searched.
The following search strategy was used: (prevalence OR
seroprevalence OR frequency OR rate OR epidemiology)
AND (“hepatitis C virus” OR “hepatitis C infection” OR
“HCV” OR “viral hepatitis” OR hepatitis OR “hepatitis C
antibodies”) AND (“injection drug users” OR “IDUs” OR
“injection substance users” OR “injection drug use” OR
“injection substance use” OR “intravenous drug users” OR
“intravenous substance users” OR “drug users” OR “sub-
stance users” OR “drug injection” OR “substance injec-
tion” OR “drug addicts” OR “substance addicts” OR
“injection drugs” OR “injection substances” OR “injecting
drug” OR “injecting substance” OR “substance injection”
OR “drug injection” OR “substance-injecting practice” OR
“drug-injecting practice” OR “inject substance” OR “inject
drug” OR “inject substance” OR “injecting drug users” OR
“injecting substance users” OR “drug injection history”
OR “substance injection history” OR “injection drug
abusers” OR “injection substance abusers” OR “drug
abusers” OR “substance abusers” OR “intravenous drug
abuse” OR “intravenous substance abuse” OR “IV drug
users” OR “IV substance users” OR “illicit drug injection”
OR “illicit substance injection” OR “people who inject
drugs” OR PWID OR “people who inject substances”)
AND Iran. Differences in selected studies between two au-
thors were resolved by consensus.
Eligibility criteria
Eligible studies were identified according to the follow-
ing PECOS (population, exposure, comparison/compara-
tor, outcome and study type) criteria: i) population:
Iranian population; ii) exposure: injection drug users; iii)
comparison/comparator: type of substance injected and
level of substance use, iv) outcome: HCV prevalence;
and v) study type: cross-sectional study.
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Inclusion criteria
Inclusion criteria were as follows: i) studies were consid-
ered eligible if published in Persian or English; ii) pub-
lished in peer-reviewed journals; iii) reporting HCV
prevalence or with sufficient data, providing the possibility
to calculate HCV prevalence among PWID; iii) using stan-
dardized tests to detect HCV, namely recombinant immu-
noblot assay (RIBA), polymerase-chain reaction (PCR) and
enzyme-linked immunosorbent assay (ELISA); iv) devised
as observational studies (of any kind: cross-sectional, co-
hort, or case-control); v) conducted in Iran; and vi) carried
out without any limitations in terms of age and gender.
Exclusion criteria
Exclusion criteria were as follows: i) studies were not
deemed eligible if devised as case reports, case-series, re-
views or systematic reviews (even though, if available,
reference lists of reviews were scanned for ensuring a
comprehensive coverage of the literature); ii) published
as conferences abstracts or in proceedings; iii) not
reporting HCV prevalence or not providing clear, suit-
able data for estimating HCV prevalence; iv) conducted
among HIV-positive individuals or subjects with other
disorders; v) not carried out in Iran; and vi) with over-
lapping/duplicate data.
Screening and data extraction
After finding potentially related studies, authors ex-
tracted relevant data and information based on ad
hoc Excel spreadsheet. Extracted data included the
surname of the first author, the study journal, the
year of publication, the number of participants exam-
ined, the type of diagnostic test performed, the num-
ber of positive HCV patients, the number of
participants stratified by gender, the reported preva-
lence, the duration of drug injection practice and the
history of using a shared syringe.
Study quality appraisal
The Joanna Brigg’s Institute (JBI) checklist was used to
check the quality of selected studies [20]. This checklist
has 10 questions and is particularly suitable for the ap-
praisal of epidemiological and prevalence studies. The an-
swer to each question is yes, no, unclear or not applicable.
Fig. 1 Process of searching, retrieving and selecting potentially relevant studies
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Table 1 Characteristics of the included studies
First name Year Mean age Province Sample No-male No-female Test Prevalence (%)
Zali 2001 34.2 Tehran 402 402 0 Elisa 45.3
Rowhani Rahbar 2004 NA Khorasan Razavi 101 NA NA Elisa 59.4
Sarvghad 2005 NA Khorasan Razavi 53 50 3 Elisa 67.92
Mohammad Alizadeh 2005 NA Hamadan 149 NA NA Elisa 31.5
Imani 2006 33.4 Shahrekord 133 131 2 Elisa 11.2
Zamani 2007 30 Tehran 202 196 6 Elisa 52
Mohtasham Amiri 2007 34.7 Guilan 81 81 0 Elisa 88.9
Aminzadeh 2007 34.4 Tehran 70 NA NA Elisa 36
Imani 2008 33.4 Chaharmahal and Bakhtiari 133 131 2 Elisa 11.2
Mir-Nasseri 2008 36 Tehran 467 464 54 Elisa NA
Soudbakhsh 2008 35.3 Tehran 60 60 0 Elisa 80
Kheirandish 2009 35 Tehran 454 NA NA Elisa 80
Mirahmadizadeh 2009 33 Tehran 1525 1465 60 Elisa 43.4
Sharif 2009 36.5 Isfahan 200 177 23 Elisa 10.5
Tajbakhsh 2009 NA Shahrekord 90 NA NA Elisa NA
Alavi 2009 26.3 Khozestan 142 NA NA Elisa 52.11
Davoodian 2009 35.4 Hormozgan 249 NA NA Elisa 64.8
Zamani 2010 23.6 Isfahan 117 114 3 Elisa 59.4
Merat 2010 NA Tehran-Hormozgan-Golestan 40 NA NA Elisa NA
Hosseini 2010 NA Tehran 417 417 0 Elisa 80
Alavi 2010 24.8 Khozestan 333 323 10 Elisa 30.9
Mir-Nasseri 2011 NA Tehran 392 464 54 Elisa NA
Keramat 2011 NA Hamadan 199 NA NA Elisa NA
Kaffashian 2011 32.6 Isfahan 951 946 5 Elisa 42
Azizi 2011 NA Kermanshah 58 NA NA Elisa 53.4
Mobasheri zadeh 2011 NA Isfahan 1055 NA NA Elisa 7
Ataei 2011 NA Isfahan 136 NA NA Elisa 19.8
Nokhodian 2012 16.59 Isfahan 6 NA NA Elisa 50
Nokhodian 2012 31.77 Isfahan 531 503 28 Elisa 47.1
Kassaian 2012 32.6 Isfahan 943 938 5 Elisa 41.6
Nobari 2012 35 Isfahan 1747 581 14 Elisa 34
Sofian 2012 30.7 Markazi 153 153 0 Elisa 59.5
Amin-Esmaeili 2012 33.9 Tehran 895 859 36 Elisa NA
Tavanaei Sani 2012 NA Khorasan Razavi 62 NA NA Elisa 71
Sarkari 2012 NA Kohgiloyeh and Boyerahmad 158 NA NA Elisa 42.2
Honarvar 2013 NA Fars 233 NA NA Elisa 40.3
Ziaee 2014 NA Southern Khorasan 25 NA NA Elisa NA
Ramezani 2014 33.3 Markazi 100 100 0 Elisa 56
Salehi 2015 20.24 Fars 222 NA NA Elisa 90
Afshari 2016 38.82 Fars 772 NA NA Elisa 14.2
Sharhani 2017 36.7 Kermanshah 606 NA NA Elisa NA
Rezaie 2017 33.2 Kermanshah 410 410 0 Elisa 42
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Table 2 Methodological assessment of the quality of selected studies
Study Was the
sample
frame
appropriate
to address
the target
population?
Were study
participants
sampled in
an
appropriate
way?
Was the
sample
size
adequate?
Were the
study
subjects
and the
setting
described
in detail?
Was the data
analysis
conducted
with sufficient
coverage of
the identified
sample?
Were valid
methods
used for the
identification
of the
condition?
Was the
condition
measured in
a standard,
reliable way
for all
participants?
Was there
appropriate
statistical
analysis?
Was the
response rate
adequate, and if
not, was the low
response rate
managed
appropriately?
Zali Y Y Y Y Y Y Y Y Y
Rowhani Rahbar Y Y Y Y Y Y Y Y Y
Sarvghad Y Y N Y Y Y Y Y Y
Mohammad
Alizadeh
Y Y Y Y Y Y Y Y Y
Imani Y Y N Y Y Y Y Y Y
Zamani Y Y U Y Y Y Y Y Y
Mohtasham
Amiri
Y Y Y Y Y Y Y Y Y
Aminzadeh Y Y Y Y Y Y Y Y Y
Imani Y Y Y Y Y Y Y Y Y
Mir-Nasseri Y Y Y Y Y Y Y Y Y
Soudbakhsh AR Y Y Y Y Y Y N Y Y
Kheirandish Y Y Y Y Y Y Y Y N
Mirahmadizadeh Y Y N Y Y Y Y Y Y
Sharif Y Y Y Y Y Y Y Y Y
Tajbakhsh Y Y U Y Y Y Y Y Y
Alavi Y Y Y Y Y Y U Y Y
Davoodian Y Y Y Y Y Y Y Y Y
Zamani Y Y Y Y Y Y Y Y N
Merat Y Y Y Y Y Y Y Y Y
Hosseini Y Y N Y Y Y Y Y Y
Alavi Y Y Y Y Y Y Y N
Mir-Nasseri Y Y Y Y Y Y U Y Y
Keramat Y Y Y Y Y Y Y Y Y
Kaffashian Y Y Y Y Y Y Y Y Y
Azizi Y Y N Y Y Y Y Y N
Mobasheri
zadeh
Y Y Y Y Y Y Y Y Y
Ataei Y Y N Y Y Y Y Y Y
Nokhodian Y Y U Y Y Y Y Y Y
Nokhodian Y Y N Y Y Y N Y Y
Kassaian Y Y Y Y Y Y N Y N
Nobari Y Y Y Y Y Y Y Y Y
Sofian Y Y Y Y Y Y Y Y Y
Amin-Esmaeili Y Y Y Y Y Y Y Y Y
Tavanaei Sani Y Y Y Y Y Y Y Y Y
Sarkari Y Y Y Y Y Y Y Y U
Honarvar Y Y U Y Y Y Y Y
Ziaee Y Y Y Y Y Y Y Y U
Ramezani Y Y N Y Y Y Y Y Y
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Statistical analysis
For all data analysis, the commercial software STATA
Ver.14 (Stata Corp, College Station, TX, USA) was used.
Figures with p-values < 0.05 were considered statistically
significant. To calculate HCV prevalence among Iranian
PWID, a random-effect model according to the
DerSimonian-Laird approach with the Freeman-Tukey
double arcsine transformation with 95% confidence interval
(CI) was used [21, 22]. For computing the amount of het-
erogeneity among studies, the I2 statistics was utilized [23].
The Egger’s linear regression test was used for assessing the
presence of publication bias [24]. Based on the age of the
participants, sample size, duration of injection (based on
the selected studies, the mean duration of injection was cal-
culated by the authors to be 3 years) and geographic region
of the study, subgroup analyses were carried out. Further-
more, sensitivity analysis was performed in order to ensure
the stability of the results. Also, to further investigate the
possible sources of heterogeneity among studies, meta-
regressions were conducted based on the year of study,
sample size and age of participants.
Results
The initial search of the literature yielded a pool of 474 re-
cords. Figure 1 shows the process of searching, retrieving
and selecting relevant studies. 68 records were duplicate
items and, as such, were removed. The title of the studies
was then reviewed and at that step 321 records were re-
moved. The abstract of the articles was reviewed and, fi-
nally, 42 studies were retained based on the above-
mentioned inclusion and exclusion criteria [25–66].
Table 1 summarizes the characteristics of the 42 stud-
ies included in the present study (all 42 investigations
were designed as cross-sectional studies). 15,072 PWID
were assessed for determining the prevalence of HCV.
Retained studies were published between 2001 and 2017.
Mean age was ranging between 20 and 42 years. All
studies used ELISA to detect HCV.
The critical methodological assessment of the quality
of selected studies is presented in Table 2, showing the
high methodological rigor of the included investigations.
According to the DerSimonian-Laird random-effect
model, the overall prevalence of HCV among PWID in
Iran was computed to be 47% (CI 95: 39–56). The preva-
lence ranged between 7 and 96%. The I2 statistics yielded
a value of 99.4%, indicating high, statistically significant
heterogeneity among studies. Figure 2 shows the forest
plot of the selected studies.
Several subgroup-analyzes were conducted to explore
the sources of heterogeneity among studies. Table 3 shows
the results based on sample size, imprisoned PWID, geo-
graphic regions, age, and duration of injection.
The sensitivity analysis was performed and based on it
the results before and after removing each study per
time did not change, showing that the results were stable
and reliable.
Based on sample size, year of publication and mean
age of participants, meta-regression analyses were con-
ducted. The findings showed that the prevalence tended
to decrease by sample size (P = 0.063) and year of publi-
cation (P = 0.039), both statistically significant. Similarly,
as the age increased, the prevalence declined in a statisti-
cally significant fashion (P = 0.061). Figure 3 shows the
results of the meta-regressions.
Six studies provided data that enabled to estimate the
odds ratio (OR) of HCV infection in terms of gender.
The OR for HCV among PWID men was about 1.46
times that of women, statistically significant and suggest-
ing that men were at higher risk of developing HCV
compared to women (Fig. 4).
Some studies assessed the impact of using a common/
shared syringe showing that individuals who used a common
syringe for injection were 3.95 times more likely to be at risk.
Figure 5 shows the odds ratio for using a common syringe.
Publication bias was evaluated by performing the
Egger’s linear regression test and we could not find any
evidence of publication bias in included studies accord-
ing to P = 0.23 (Fig. 6).
Discussion
Planning to implement appropriate and effective pro-
grams to prevent and control diseases requires the use
Table 2 Methodological assessment of the quality of selected studies (Continued)
Study Was the
sample
frame
appropriate
to address
the target
population?
Were study
participants
sampled in
an
appropriate
way?
Was the
sample
size
adequate?
Were the
study
subjects
and the
setting
described
in detail?
Was the data
analysis
conducted
with sufficient
coverage of
the identified
sample?
Were valid
methods
used for the
identification
of the
condition?
Was the
condition
measured in
a standard,
reliable way
for all
participants?
Was there
appropriate
statistical
analysis?
Was the
response rate
adequate, and if
not, was the low
response rate
managed
appropriately?
Salehi Y Y Y Y Y Y Y Y Y
Afshari Y Y Y Y Y Y Y Y Y
Sharhani Y Y Y Y Y Y Y Y Y
Rezaie Y Y Y Y Y Y Y Y Y
(Y Yes, N No, U Unclear, NA Not Applicable)
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of robust and updated scientific evidence. The aim of
this study was to determine the prevalence of HCV
among the PWID, a well-known high-risk group for de-
veloping HCV. The findings of this study showed that
the prevalence was 47%. This was higher than the preva-
lence of HCV among prisoners (28%) [67], thalassemia
patients (19%) [68], street children (2.4%) [69], blood do-
nors (0.5%) [70] and the general population (0.6%) [14].
This high rate confirms that, as it is well-known, PWID
are one of the most important and high-risk groups for
developing HCV [2, 71].
The prevalence of HCV among PWID in Iran was
lower than the rate reported in other countries, in-
cluding South Africa (55%) [72], Pakistan (72%) [73]
and India (53.7%) [74] but higher than in studies con-
ducted in Kuwait (12.28%) [4], Kingdom of Saudi
Arabia (42.7%) [75], and Brazil (35.6%) [76]. These
differences in prevalence can be attributed to
Fig. 2 The forest plot of the studies included in the present systematic review and meta-analysis
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differences in health systems, screening methods, and
the type of high-risk behaviors of individuals [77, 78].
In particular, in developing countries, harm reduction
programs such as syringe distribution are not fully
implemented [79]. Furthermore, because of the high
cost of diagnostic services, many PWID are not aware
of their health status. The high cost of management
and the lack of referral for treatment can also be
some of the reasons explaining the contrasting find-
ings among various studies [80, 81].
The findings of this study showed that the highest preva-
lence of HCV among PWID in Iran was observed in East
and South of Iran (60%). Neighborhood of countries such as
Afghanistan and Pakistan could explain, at least partially,
such findings [82]. Moreover, there are a lot of harbors in
Southern Iran, which is one of the ways to transport narcotic
drugs to other countries. For this reason, addicts in the area
from Iran have easy access conditions. One of the most im-
portant policies implemented by the government in Iran is a
serious struggle against the narcotics commerce and sale,
with the support of international organizations [83].
Moreover, the findings of this study showed that the
prevalence of HCV in men was higher than that among
women, which was consistent with the results of studies
performed in India [84] as well as in upper middle-
income countries [78]. Men were found to be more
Table 3 Sub-group analyses based on sample size, geographical region, age, duration of injection and type of study
Variable No study Prevalence 95% Confidence interval (CI) I2 P – value
Sample size
≤ 200 22 56% (44–68) 99% 0.00
> 200 20 37% (29–46) 98.1% 0.00
Region
North 1 26% (22–30) – –
West 9 39% (26–53) 98.6% 0.00
South 9 59% (41–78) 96.8% 0.00
East 4 61% (43–76) 92.2% 0.00
Central 19 44% (31–62) 97.3% 0.00
Age 0.00
≤ 30 7 53% (35–71) 94.3% 0.00
> 30 20 45% (33–56) 98.4% 0.00
NA 15 49% (33–64) 97.3% 0.00
Duration of injection (years)
≤ 3 12 57% (26–68) 92.7% 0.00
> 3 11 52% (41–83) 98.3% 0.00
NA 19 48% (34–59) 97.1% 0.00
Type of participants
Only prisoners 10 52% (38–67) 98.5% 0.00
Non-prisoners 28 45% (36–54) 99.2% 0.00
Both (Non-prisoners and prisoners) 4 53% (17–89) 99.6% 0.00
Fig. 3 Findings of the meta-regressions based on sample size, year of publication and mean age of participants
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likely to be at risk than women, probably due to differ-
ences in lifestyles and behaviors that make men more
susceptible to HCV. The cultural and social conditions
in Iran have led men to become more oriented toward
injecting drug use than women. As such, most of the
participants evaluated in the studies included in the
present systematic review and meta-analysis were male.
The findings showed that the prevalence of infections in
people who had a history less than 3 years of injection was
higher than the rate among those who had an injection
history longer than 3 years. A reason could be the early
detection of the disease in these people. Unfortunately,
one of the problems with HCV is that many people are
not aware of their illness, not having access to diagnostic
services, due to the expensive testing costs, and the lack of
motivation to diagnose possible illnesses [27, 52, 58, 65].
PWID that had a history of sharing needles had a
3.95-fold increased risk of developing HCV infection,
which is in line with the literature [4, 85]. Various stud-
ies have shown that needle exchange programs (NEP)
can be used as a harm reduction policy to decrease HCV
prevalence among PWID, even though the effectiveness
of this program has yet to be properly verified [86, 87].
Meta-regressions showed that the prevalence of HCV
among PWID in Iran has decreased in recent years, even
though not in a statistically significant way. This de-
crease reflects the widespread effort to reduce HCV-
related risk of diffusion and transmission. Health policy-
and decision-makers in Iran have adopted valuable harm
reduction policies to prevent and control HCV among
high-risk groups, and especially PWID. The Ministry of
Health, as the most important actor in controlling the
disease, has been developing educational programs for the
general population, as well as for the high-risk groups. Es-
tablishing centers in all provinces for the distribution of
syringes, condoms and alternative treatments such as
methadone has enabled to obtain good results. In these
centers, diagnostic tests are performed free of charge for
PWID and others who have high-risk behaviors. The sup-
port of the judiciary system in Iran has led to a serious
emphasis on screening programs in Iranian prisons. There
are also special centers for women who offer harm reduc-
tion services. All these activities have contributed to con-
trolling the disease.
The findings of the present study showed that the preva-
lence of HCV was higher in studies involving only prisoners
(52%) compared to studies involving non-prisoners (45%).
Prison for individuals can be an important risk factor for
injecting drug use (IDU) [88]. The absence or inappropriate
implementation of risk reduction policies in prisons around
the world has led to serious problems for prisoners [89].
The pattern of drug use in Iran has changed in recent de-
cades and IDUs are on the rise [67]. In one sense, prisoners
practicing IDU are more susceptible to infections such as
HBV, HCV and HIV than others [90].
However, this study has some limitations, which
should be properly acknowledged. Epidemiological
studies of HCV prevalence among PWID were not
performed in all provinces and areas of Iran. There-
fore, it is necessary to conduct observational surveys
in all provinces in order to obtain a clear under-
standing of the disease condition. High amounts of
heterogeneity as shown by the I2 statistics indicate
that there are methodological differences among
Fig. 4 HCV prevalence stratified by gender
Fig. 5 HCV prevalence stratified by the history of sharing needles
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studies, as indicated also by the subgroup analysis.
Other limitations include the lack of sufficient quan-
titative data from some studies that hindered the
possibility of computing HCV prevalence, especially
stratifying by age-groups and gender.
Conclusion
The findings of the present study showed that the preva-
lence of HCV among PWIDs in Iran is high. The sup-
port and implementation of ad hoc health-related
policies and programs that reduce this should be put
into action. Alternative treatments such as methadone
therapy and HCV therapy can help control the problem.
Health policy- and decision-makers in Iran should pro-
vide faster diagnosis and access to low-cost health care.
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